JP2019523301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523301A5 JP2019523301A5 JP2019526201A JP2019526201A JP2019523301A5 JP 2019523301 A5 JP2019523301 A5 JP 2019523301A5 JP 2019526201 A JP2019526201 A JP 2019526201A JP 2019526201 A JP2019526201 A JP 2019526201A JP 2019523301 A5 JP2019523301 A5 JP 2019523301A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- days
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 110
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 59
- 238000002560 therapeutic procedure Methods 0.000 claims 46
- 239000012270 PD-1 inhibitor Substances 0.000 claims 34
- 239000012668 PD-1-inhibitor Substances 0.000 claims 34
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 34
- 210000004027 cell Anatomy 0.000 claims 22
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 16
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 16
- 238000012986 modification Methods 0.000 claims 16
- 230000004048 modification Effects 0.000 claims 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 10
- -1 CD86 Proteins 0.000 claims 7
- 206010052015 cytokine release syndrome Diseases 0.000 claims 6
- 102100022339 Integrin alpha-L Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 4
- 239000012642 immune effector Substances 0.000 claims 4
- 229940121354 immunomodulator Drugs 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 3
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 3
- 102100025390 Integrin beta-2 Human genes 0.000 claims 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 102100029197 SLAM family member 6 Human genes 0.000 claims 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 102100024263 CD160 antigen Human genes 0.000 claims 2
- 102100038077 CD226 antigen Human genes 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 2
- 102100039904 Integrin alpha-D Human genes 0.000 claims 2
- 102100022341 Integrin alpha-E Human genes 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 108010017009 CD11b Antigen Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000650806 Homo sapiens Semaphorin-3F Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 108010041100 Integrin alpha6 Proteins 0.000 claims 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims 1
- 102100033016 Integrin beta-7 Human genes 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 108091008877 NK cell receptors Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 102000014128 RANK Ligand Human genes 0.000 claims 1
- 108010025832 RANK Ligand Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100029216 SLAM family member 5 Human genes 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 102100027751 Semaphorin-3F Human genes 0.000 claims 1
- 102100027744 Semaphorin-4D Human genes 0.000 claims 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022036315A JP2022088432A (ja) | 2016-07-28 | 2022-03-09 | キメラ抗原受容体とｐｄ－１阻害薬との併用療法 |
| JP2024129900A JP2024167225A (ja) | 2016-07-28 | 2024-08-06 | キメラ抗原受容体とｐｄ－１阻害薬との併用療法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368100P | 2016-07-28 | 2016-07-28 | |
| US62/368,100 | 2016-07-28 | ||
| US201762455547P | 2017-02-06 | 2017-02-06 | |
| US62/455,547 | 2017-02-06 | ||
| US201762482846P | 2017-04-07 | 2017-04-07 | |
| US62/482,846 | 2017-04-07 | ||
| US201762514542P | 2017-06-02 | 2017-06-02 | |
| US62/514,542 | 2017-06-02 | ||
| PCT/US2017/044425 WO2018023025A1 (en) | 2016-07-28 | 2017-07-28 | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036315A Division JP2022088432A (ja) | 2016-07-28 | 2022-03-09 | キメラ抗原受容体とｐｄ－１阻害薬との併用療法 |
| JP2024129900A Division JP2024167225A (ja) | 2016-07-28 | 2024-08-06 | キメラ抗原受容体とｐｄ－１阻害薬との併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019523301A JP2019523301A (ja) | 2019-08-22 |
| JP2019523301A5 true JP2019523301A5 (cg-RX-API-DMAC7.html) | 2020-09-10 |
Family
ID=59700172
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526201A Withdrawn JP2019523301A (ja) | 2016-07-28 | 2017-07-28 | キメラ抗原受容体とｐｄ−１阻害薬との併用療法 |
| JP2022036315A Pending JP2022088432A (ja) | 2016-07-28 | 2022-03-09 | キメラ抗原受容体とｐｄ－１阻害薬との併用療法 |
| JP2024129900A Pending JP2024167225A (ja) | 2016-07-28 | 2024-08-06 | キメラ抗原受容体とｐｄ－１阻害薬との併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036315A Pending JP2022088432A (ja) | 2016-07-28 | 2022-03-09 | キメラ抗原受容体とｐｄ－１阻害薬との併用療法 |
| JP2024129900A Pending JP2024167225A (ja) | 2016-07-28 | 2024-08-06 | キメラ抗原受容体とｐｄ－１阻害薬との併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190151365A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3491016A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019523301A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20250061769A (cg-RX-API-DMAC7.html) |
| CN (3) | CN118021943A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017302668B9 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019001570A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3032054A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL316970A (cg-RX-API-DMAC7.html) |
| MY (1) | MY205684A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201900677SA (cg-RX-API-DMAC7.html) |
| TW (2) | TW201806619A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018023025A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2958942B1 (en) | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| ES2760023T3 (es) | 2013-02-20 | 2020-05-12 | Univ Pennsylvania | Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| JP6736540B2 (ja) | 2014-07-21 | 2020-08-05 | ノバルティス アーゲー | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| WO2016028896A1 (en) | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| BR112017005390A2 (pt) | 2014-09-17 | 2017-12-12 | Novartis Ag | células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva |
| IL279420B2 (en) | 2014-10-08 | 2024-09-01 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| HRP20220893T1 (hr) | 2015-04-08 | 2022-10-14 | Novartis Ag | Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CA2992551A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| SG10202109655VA (en) | 2015-12-04 | 2021-10-28 | Novartis Ag | Compositions and methods for immunooncology |
| WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| CA3039646A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| IL292551B2 (en) | 2016-10-07 | 2023-10-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
| MX2019004181A (es) | 2016-10-13 | 2019-10-30 | Juno Therapeutics Inc | Métodos y composiciones de inmunoterapia que implican moduladores de la ruta metabólica de triptófano. |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3055202A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Cd19 compositions and methods for immunotherapy |
| SG11201907434RA (en) | 2017-03-22 | 2019-10-30 | Novartis Ag | Compositions and methods for immunooncology |
| TW202428622A (zh) | 2017-10-18 | 2024-07-16 | 瑞士商諾華公司 | 用於選擇性蛋白質降解的組合物及方法 |
| CA3082334A1 (en) * | 2017-11-20 | 2019-05-23 | Julius-Maximilians-Universitat Wurzburg | Cd19cart cells eliminate myeloma cells that express very low levels of cd19 |
| MX2020006530A (es) * | 2017-12-22 | 2020-10-15 | Codagenix Inc | Virus recombinante con region desoptimizada de par de codones y usos del mismo para el tratamiento de cancer. |
| JP2021510539A (ja) | 2018-01-16 | 2021-04-30 | シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置 |
| CN108424927A (zh) * | 2018-02-10 | 2018-08-21 | 武汉波睿达生物科技有限公司 | 一种能同时表达cd19 car和敲低t细胞表面pd-1表达的质粒结构及其构建方法 |
| EP3762023A4 (en) * | 2018-03-05 | 2021-12-29 | New York University | Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins |
| EP3806962A1 (en) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma chimeric antigen receptors and uses thereof |
| CA3114002A1 (en) * | 2018-09-25 | 2020-04-02 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| SG11202104524YA (en) | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| WO2020102779A1 (en) | 2018-11-16 | 2020-05-22 | Albert Einstein College Of Medicine | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF |
| WO2020172553A1 (en) * | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| CA3134511A1 (en) * | 2019-03-22 | 2020-10-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN111743923B (zh) * | 2019-03-27 | 2024-11-08 | 北京康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 |
| CN110408698B (zh) * | 2019-06-17 | 2023-05-30 | 重庆医科大学附属第二医院 | 肝癌的新诊治标志物lncRNA-LALR1及应用 |
| EP3986442A4 (en) * | 2019-06-21 | 2023-10-25 | Shattuck Labs, Inc. | Chimeric protein expressing t-cells |
| WO2021020564A1 (ja) * | 2019-08-01 | 2021-02-04 | 国立大学法人三重大学 | Ｇｄ２結合性分子 |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| CN110592140A (zh) * | 2019-09-30 | 2019-12-20 | 王清路 | Pd-1基因缺陷型pd-1-cart细胞制剂的制法 |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| WO2021108613A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| WO2021127428A1 (en) * | 2019-12-18 | 2021-06-24 | Albert Einstein College Of Medicine | Chimeric antigen receptors targeting b7-h3 (cd276) and associated methods |
| CN113150167A (zh) * | 2020-01-22 | 2021-07-23 | 中国人民解放军总医院第五医学中心 | 一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计 |
| JP2023529460A (ja) * | 2020-06-09 | 2023-07-10 | ハンチョウ リーディング エッジ ファーマシューティカル リミテッド | 免疫応答を増強するための組成物および方法 |
| US20230374160A1 (en) * | 2020-10-02 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
| CA3203945A1 (en) * | 2021-01-08 | 2022-07-14 | Dmitry Dmitrievich Genkin | Combination of deoxyribonuclease enzyme and cell therapies for treatment of cancer |
| AU2022246593A1 (en) * | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| US20240245722A1 (en) | 2021-05-25 | 2024-07-25 | Vaxcell-Bio | Monobody-based chimeric antigen receptor and immune cell including same |
| EP4384621A4 (en) * | 2021-08-09 | 2025-04-09 | The Trustees of The University of Pennsylvania | OPTIMIZATION OF T LYMPHOCYTE DIFFERENTIATION STATE WITH MICRORNAS |
| US20230137343A1 (en) * | 2021-10-06 | 2023-05-04 | Walking Fish Therapeutics, Inc. | Methods and compositions for enhancing activity of t cells with modified b cells |
| WO2023076811A1 (en) * | 2021-10-26 | 2023-05-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Combination therapies with chimeric antigen receptors |
| JP2025508020A (ja) | 2022-03-08 | 2025-03-21 | ヴァクセル－バイオ | Ｐｄ－ｌ１特異的キメラ抗原受容体及びそれを含む免疫細胞 |
| WO2024012585A1 (zh) * | 2022-07-14 | 2024-01-18 | 达仁生物科技有限公司 | Nkg2d嵌合抗原受体和pd1抑制剂联合治疗癌症的方法和药物 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024215881A1 (en) * | 2023-04-11 | 2024-10-17 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2025012900A1 (en) * | 2023-07-10 | 2025-01-16 | Pluri Biotech Ltd. | Genetically engineered mucosal-associated invariant t (mait) cells for adoptive transfer celltherapy |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4433059A (en) | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| JPH021556A (ja) | 1988-06-09 | 1990-01-05 | Snow Brand Milk Prod Co Ltd | ハイブリッド抗体及びその作製方法 |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5273743A (en) | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| RU2128709C1 (ru) | 1992-01-23 | 1999-04-10 | Мерк Патент Гмбх | Способ получения димерного одноцепочечного слитого белка (варианты) |
| ATE295420T1 (de) | 1992-02-06 | 2005-05-15 | Chiron Corp | Marker für krebs und biosynthetisches bindeprotein dafür |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| CA2135408A1 (en) | 1992-05-08 | 1993-11-25 | Peter C. Keck | Chimeric multivalent protein analogues and methods of use thereof |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| PT1589107E (pt) | 1992-08-21 | 2010-03-29 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP1550729B1 (en) | 1992-09-25 | 2009-05-27 | Avipep Pty Limited | Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| GB9323648D0 (en) | 1992-11-23 | 1994-01-05 | Zeneca Ltd | Proteins |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| EP0787185A2 (en) | 1994-10-20 | 1997-08-06 | MorphoSys AG | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| WO1996037621A2 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Multimeric proteins |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| DE69730209T2 (de) | 1996-04-04 | 2005-04-14 | Unilever N.V. | Multivalentes und multispezifisches Antigenbindungsprotein |
| US6323322B1 (en) | 1997-04-30 | 2001-11-27 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| EP1012280B1 (en) | 1997-06-11 | 2004-11-10 | Borean Pharma A/S | Trimerising module |
| DE69839147T2 (de) | 1997-06-12 | 2009-02-19 | Novartis International Pharmaceutical Ltd. | Künstliche antikörperpolypeptide |
| ATE461282T1 (de) | 1997-10-27 | 2010-04-15 | Bac Ip Bv | Multivalente antigenbindende proteine |
| AU2719099A (en) | 1998-01-23 | 1999-08-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
| CZ121599A3 (cs) | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| AU5728999A (en) | 1998-07-28 | 2000-02-21 | Micromet Ag | Heterominibodies |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| JP2004500095A (ja) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ， インコーポレイテッド | 細胞の同時の刺激および濃縮 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| JP2004511430A (ja) | 2000-05-24 | 2004-04-15 | イムクローン システムズ インコーポレイティド | 二重特異性免疫グロブリン様抗原結合蛋白および製造方法 |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
| AU2001283496A1 (en) | 2000-07-25 | 2002-02-05 | Immunomedics, Inc. | Multivalent target binding protein |
| EP2351838A1 (en) | 2000-10-20 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Crosslinking agonistic antibodies |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| AU2002247826A1 (en) | 2001-03-13 | 2002-09-24 | University College London | Specific binding members |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| AU2002319544B2 (en) | 2001-08-10 | 2008-07-10 | Aberdeen University | Antigen binding domains from fish |
| ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
| AU2002357072A1 (en) | 2001-12-07 | 2003-06-23 | Centocor, Inc. | Pseudo-antibody constructs |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| JP4386741B2 (ja) | 2002-04-15 | 2009-12-16 | 中外製薬株式会社 | ｓｃＤｂライブラリーの作成方法 |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| GB0305702D0 (en) | 2003-03-12 | 2003-04-16 | Univ Birmingham | Bispecific antibodies |
| JP2006526408A (ja) | 2003-04-22 | 2006-11-24 | アイビーシー、ファーマシューティカルズ | 多価タンパク質複合体 |
| JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| CA2536238C (en) | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
| CA2537055A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| AU2004308439A1 (en) | 2003-12-22 | 2005-07-14 | Centocor, Inc. | Methods for generating multimeric molecules |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| US8383575B2 (en) | 2004-01-30 | 2013-02-26 | Paul Scherrer Institut | (DI)barnase-barstar complexes |
| WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
| US20060204493A1 (en) | 2004-09-02 | 2006-09-14 | Genentech, Inc. | Heteromultimeric molecules |
| EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| AU2006232920B2 (en) | 2005-04-06 | 2011-09-29 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| NZ597168A (en) | 2005-08-19 | 2013-07-26 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| DE602005018477D1 (de) | 2005-08-26 | 2010-02-04 | Pls Design Gmbh | Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| US8623356B2 (en) | 2005-11-29 | 2014-01-07 | The University Of Sydney | Demibodies: dimerization-activated therapeutic agents |
| CA2638794A1 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
| MX2008011874A (es) | 2006-03-17 | 2009-01-07 | Biogen Idec Inc | Composiciones estabilizadas de polipeptidos. |
| WO2007112362A2 (en) | 2006-03-24 | 2007-10-04 | The Regents Of The University Of California | Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| US8501185B2 (en) | 2006-05-25 | 2013-08-06 | Bayer Healthcare Llc | Dimeric molecular complexes |
| US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| WO2008022349A2 (en) | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
| KR20090105913A (ko) | 2006-11-02 | 2009-10-07 | 다니엘 제이 카폰 | 이동 부분을 갖는 하이브리드 면역글로불린 |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| NZ600758A (en) * | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| WO2009021754A2 (en) | 2007-08-15 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
| US20110189203A1 (en) | 2007-11-27 | 2011-08-04 | Ablynx N.V. | Immunoglobulin constructs |
| AR069495A1 (es) | 2007-11-30 | 2010-01-27 | Glaxo Group Ltd | Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis) |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| ES2708124T3 (es) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedimiento para preparar moléculas heteromultiméricas |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| TR201815488T4 (tr) | 2011-04-08 | 2018-11-21 | Health | Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı. |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| CA2863799C (en) | 2012-02-22 | 2020-09-01 | Matthew J. FRIGAULT | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| AR092745A1 (es) | 2012-10-01 | 2015-04-29 | Univ Pennsylvania | Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| ES2760023T3 (es) | 2013-02-20 | 2020-05-12 | Univ Pennsylvania | Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado |
| EP2958942B1 (en) | 2013-02-20 | 2020-06-03 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| ES2831315T3 (es) | 2013-04-03 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | Generación efectiva de células T dirigidas al tumor derivadas de células madre pluripotentes |
| BR112016013187A2 (pt) | 2013-12-19 | 2017-09-26 | Novartis Ag | receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| PL3888674T3 (pl) | 2014-04-07 | 2024-09-23 | Novartis Ag | Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19 |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| JP6736540B2 (ja) | 2014-07-21 | 2020-08-05 | ノバルティス アーゲー | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
| EP4205749A1 (en) * | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
| WO2016028896A1 (en) * | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| IL279420B2 (en) * | 2014-10-08 | 2024-09-01 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| WO2016064929A1 (en) * | 2014-10-20 | 2016-04-28 | Juno Therapeutics, Inc. | Methods and compositions for dosing in adoptive cell therapy |
| HRP20220893T1 (hr) | 2015-04-08 | 2022-10-14 | Novartis Ag | Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor |
-
2017
- 2017-07-28 EP EP17757594.1A patent/EP3491016A1/en active Pending
- 2017-07-28 TW TW106125631A patent/TW201806619A/zh unknown
- 2017-07-28 IL IL316970A patent/IL316970A/en unknown
- 2017-07-28 CN CN202410141903.5A patent/CN118021943A/zh active Pending
- 2017-07-28 US US16/321,322 patent/US20190151365A1/en active Pending
- 2017-07-28 IL IL264486A patent/IL264486B2/en unknown
- 2017-07-28 CN CN201780059525.4A patent/CN110214150A/zh active Pending
- 2017-07-28 AU AU2017302668A patent/AU2017302668B9/en active Active
- 2017-07-28 SG SG11201900677SA patent/SG11201900677SA/en unknown
- 2017-07-28 BR BR112019001570-1A patent/BR112019001570A2/pt unknown
- 2017-07-28 KR KR1020257012937A patent/KR20250061769A/ko active Pending
- 2017-07-28 KR KR1020237020747A patent/KR20230100748A/ko not_active Ceased
- 2017-07-28 WO PCT/US2017/044425 patent/WO2018023025A1/en not_active Ceased
- 2017-07-28 MY MYPI2019000493A patent/MY205684A/en unknown
- 2017-07-28 KR KR1020197005490A patent/KR20190034588A/ko not_active Ceased
- 2017-07-28 CA CA3032054A patent/CA3032054A1/en active Pending
- 2017-07-28 CN CN202410141560.2A patent/CN117959417A/zh active Pending
- 2017-07-28 TW TW113117474A patent/TW202508628A/zh unknown
- 2017-07-28 JP JP2019526201A patent/JP2019523301A/ja not_active Withdrawn
-
2022
- 2022-03-09 JP JP2022036315A patent/JP2022088432A/ja active Pending
-
2023
- 2023-12-18 AU AU2023284778A patent/AU2023284778A1/en not_active Withdrawn
-
2024
- 2024-08-06 JP JP2024129900A patent/JP2024167225A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523301A5 (cg-RX-API-DMAC7.html) | ||
| JP2018538339A5 (cg-RX-API-DMAC7.html) | ||
| JP2025032091A5 (cg-RX-API-DMAC7.html) | ||
| RU2017105160A (ru) | Лечение рака с помощью химерного антигенного рецептора к cd33 | |
| JP2017524367A5 (cg-RX-API-DMAC7.html) | ||
| RU2017108903A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| JP2017530694A5 (cg-RX-API-DMAC7.html) | ||
| RU2017105065A (ru) | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма | |
| RU2017105161A (ru) | Лечение рака с использованием химерного антигенного рецептора cll-1 | |
| IL317912A (en) | A combined chimeric antigen receptor targeting CD19 and CD20 and its applications | |
| JP2017522879A5 (cg-RX-API-DMAC7.html) | ||
| JP2017527271A5 (cg-RX-API-DMAC7.html) | ||
| JP2017522880A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2016028896A5 (cg-RX-API-DMAC7.html) | ||
| JP2022040287A5 (cg-RX-API-DMAC7.html) | ||
| HRP20221348T1 (hr) | Kimerni receptori i postupci njihove uporabe | |
| JP2018518939A5 (cg-RX-API-DMAC7.html) | ||
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2019525956A5 (cg-RX-API-DMAC7.html) | ||
| JP2018527014A5 (cg-RX-API-DMAC7.html) | ||
| CA2961636A1 (en) | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | |
| JP2019515661A5 (cg-RX-API-DMAC7.html) | ||
| RU2020100865A (ru) | Лечение рака с помощью гуманизированного анти-cd19 химерного антигенного рецептора | |
| RU2021121771A (ru) | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19 | |
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe |